The Company is engaged in the discovery, development and commercialization of products for cancer treatment and protection of normal tissues from radiation and toxins.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
I think I'll let guest contributor M. E. Garza help write my pitch for Cleveland Biolabs with the nine Seeking Alpha article titles he wrote from Feb 2010 through March 2011
2/24/10 (share price 3.86): Is Cleveland BioLabs Ready to Move Higher?
Yes, M.E., but not yet. First you'll have to drop this article:
8/27/10 (share price 3.95) Interview: Cleveland BioLabs CEO Discusses Recent Developments, Milestones Ahead
Now that's got something going. But let's juice it a little bit.
10/3/10: (share price 5.07) Investment Risk in Cleveland BioLabs Has Been Wiped Off the Table
You've got to love that last title. A speculative biopharma with NO investment risk. Hallelujah.
10/17/10 (share price 6.29) Cleveland BioLabs' Unfounded Fear of Dilution
Totally unfounded. When has a large shelf registration ever meant that a dilution was on the way?
11/30/10 (share price 6.18) New Orphan Drug Status May Boost Cleveland BioLabs Shares
Yes, orphan drug status is always a huge boost to the bottom line. Now you just need a few years of success in clinical trials and FDA approval and you're golden.
1/1/11 (share price 7.19) Cleveland Biolabs Anti-Cancer Effect Brings Potential Value
Happy New Year Garza. This one is getting close to the peak.
2/2/11 (share price 6.6) Jumping on the Cleveland Biolabs Bandwagon
That refers to Wedbush Securities initiating coverage with an outperform rating. Oh yes, sell-side analyst ratings. I didn't even have the energy to see whether Wedbush had already arranged a financing for them or if they were just looking for their business.
3/15/11 (share price 7.94) Looking for Squeeze Pressure on Cleveland BioLabs
That's a little attempt at profiteering from the Fukushima earthquake.
3/22/11 (share price 7.54) Cleveland Biolabs: Shares Could Head Higher After Quake Confusion
More Fukushima profiteering. How high can this stock get pumped?
Not much higher, apparently. In May the share price started to slide as the manipulators and speculators exited the stock (were you with them, Garza?). Then in June dreams of a BARDA contract started to unravel after the DoD stated that the company would have to resubmit their proposal after the FDA had reviewed the IND for CBLB502. Shortly afterward, the company executed that 24M dilutive financing (the fear of which was unfounded).
After dropping 70% from the April peak, the stock recovered a little ground in late 2011 and early 2012 before crashing again when BARDA formally expressed their disinterest in CBLB502. The share price dropped as low as 1.21 before a spike over 2 on some positive primate data for CBLB502. A subsequent steady decline has brought the share price back close to those all-time lows.
Needless to say, Garza hasn't weighed in on his risk-free stock since it crashed and burned. I'll flag them with a green thumb here, betting on a resurgence once the CBLB502 BLA is submitted and accepted. However, this will never be a low risk stock, given management's history of misrepresentation of their prospects and their collusion with shady stock promoters.